AbCellera Prices $200M Oversubscribed Offering at $9.75/Share
ABCL has more than doubled off its 52-week low of $2.745 on elevated volume (2.5× avg).
Summary
AbCellera priced its $200M public offering at $9.75 per share, with net proceeds of ~$187M to fund its internal pipeline, including lead program ABCL635.
Key Events · Financing and Capital Events · ABCL
-
Offering Priced at $9.75/Share
17,435,897 common shares priced at $9.75 per share and 3,076,926 pre-funded warrants at $9.74999 per warrant, for total gross proceeds of approximately $200 million.
-
Net Proceeds of ~$187M
After underwriting discounts, commissions, and estimated expenses, net proceeds are approximately $187.0 million, to be used for research, development, and clinical advancement of the internal pipeline, including ABCL635, and for working capital.
-
Oversubscribed Offering
The offering was oversubscribed, indicating strong institutional demand following positive Phase 2 data for ABCL635 announced on August 10, 2026.
-
Underwriting Syndicate
Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, and BMO Capital Markets acted as joint book-running managers, with specific allocations detailed in the underwriting agreement.
Analysis · ABCL · Life Sciences
AbCellera finalized terms of its $200 million public offering, pricing 17.4 million common shares at $9.75 and 3.1 million pre-funded warrants at $9.74999. The deal is oversubscribed and priced at a modest discount to the recent market price, reflecting strong institutional demand following positive Phase 2 data for ABCL635. Net proceeds of approximately $187 million will fund the internal pipeline, including the lead program ABCL635, and extend the company's cash runway. The offering is dilutive to existing shareholders but provides critical capital for clinical advancement.
At the time of this filing, ABCL was trading at $10.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $2.75 to $11.07. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.